Association of respiratory symptoms and lung function with occupation in the multinational Burden of Obstructive Lung Disease (BOLD) study.


Journal

The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460

Informations de publication

Date de publication:
01 2023
Historique:
received: 13 03 2022
accepted: 02 08 2022
pubmed: 27 8 2022
medline: 17 1 2023
entrez: 26 8 2022
Statut: epublish

Résumé

Chronic obstructive pulmonary disease has been associated with exposures in the workplace. We aimed to assess the association of respiratory symptoms and lung function with occupation in the Burden of Obstructive Lung Disease study. We analysed cross-sectional data from 28 823 adults (≥40 years) in 34 countries. We considered 11 occupations and grouped them by likelihood of exposure to organic dusts, inorganic dusts and fumes. The association of chronic cough, chronic phlegm, wheeze, dyspnoea, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV Overall, working in settings with potentially high exposure to dusts or fumes was associated with respiratory symptoms but not lung function differences. The most common occupation was farming. Compared to people not working in any of the 11 considered occupations, those who were farmers for ≥20 years were more likely to have chronic cough (OR 1.52, 95% CI 1.19-1.94), wheeze (OR 1.37, 95% CI 1.16-1.63) and dyspnoea (OR 1.83, 95% CI 1.53-2.20), but not lower FVC (β=0.02 L, 95% CI -0.02-0.06 L) or lower FEV At a population level, the occupational exposures considered in this study do not appear to be major determinants of differences in lung function, although they are associated with more respiratory symptoms. Because not all work settings were included in this study, respiratory surveillance should still be encouraged among high-risk dusty and fume job workers, especially in low- and middle-income countries.

Sections du résumé

BACKGROUND
Chronic obstructive pulmonary disease has been associated with exposures in the workplace. We aimed to assess the association of respiratory symptoms and lung function with occupation in the Burden of Obstructive Lung Disease study.
METHODS
We analysed cross-sectional data from 28 823 adults (≥40 years) in 34 countries. We considered 11 occupations and grouped them by likelihood of exposure to organic dusts, inorganic dusts and fumes. The association of chronic cough, chronic phlegm, wheeze, dyspnoea, forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV
RESULTS
Overall, working in settings with potentially high exposure to dusts or fumes was associated with respiratory symptoms but not lung function differences. The most common occupation was farming. Compared to people not working in any of the 11 considered occupations, those who were farmers for ≥20 years were more likely to have chronic cough (OR 1.52, 95% CI 1.19-1.94), wheeze (OR 1.37, 95% CI 1.16-1.63) and dyspnoea (OR 1.83, 95% CI 1.53-2.20), but not lower FVC (β=0.02 L, 95% CI -0.02-0.06 L) or lower FEV
CONCLUSION
At a population level, the occupational exposures considered in this study do not appear to be major determinants of differences in lung function, although they are associated with more respiratory symptoms. Because not all work settings were included in this study, respiratory surveillance should still be encouraged among high-risk dusty and fume job workers, especially in low- and middle-income countries.

Identifiants

pubmed: 36028253
pii: 13993003.00469-2022
doi: 10.1183/13993003.00469-2022
pmc: PMC9834632
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 085790/Z/08/Z
Pays : United Kingdom

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: J. Ratanachina, A.F.S. Amaral, S. De Matteis, H. Lawin, K. Mortimer, D.O. Obaseki, I. Harrabi, M. Denguezli, E.F.M. Wouters, C. Janson, A. Gulsvik, H.H. Cherkaski, F. Mejza, P.A. Mahesh, A. Elsony, R. Ahmed, W. Tan, L.C. Loh, A. Rashid, M. Studnicka, A.A. Nafees, T. Seemungal, A. Aquart-Stewart, M. Al Ghobain, J. Zheng, S. Juvekar, S. Salvi, R. Jogi, T. Gislason, A.S. Buist, P. Cullinan and P. Burney have no conflict of interest to disclose. R. Nielsen reports grants from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline and Novartis, and receipt of equipment/material/services from ResMed Norway; and is President of the Norwegian Respiratory Society. D. Mannino reports royalties from Up to Date; personal fees from GlaxoSmithKline, AstraZeneca and Schlesinger Law Firm; honoraria from American Association of Respiratory Care; and stock in GlaxoSmithKline; and is the Medical Director of the COPD Foundation.

Références

BMJ. 2015 Mar 16;350:h1435
pubmed: 25778910
Am J Respir Crit Care Med. 2017 Sep 12;197(5):595-610
pubmed: 28895752
Occup Environ Med. 2002 Sep;59(9):575-93; discussion 594
pubmed: 12205230
Br Med Bull. 2012;104:143-61
pubmed: 23080418
Int J Tuberc Lung Dis. 2020 Jan 1;24(1):8-21
pubmed: 32005302
Respir Med. 2011 Oct;105(10):1507-15
pubmed: 21549584
Eur Respir J. 2019 Jul 18;54(1):
pubmed: 31248951
Thorax. 2018 Nov;73(11):1008-1015
pubmed: 29574416
Br Med J. 1977 Jun 25;1(6077):1645-8
pubmed: 871704
Am J Respir Crit Care Med. 1995 Sep;152(3):1107-36
pubmed: 7663792
Am J Respir Crit Care Med. 2021 Jun 1;203(11):1353-1365
pubmed: 33171069
COPD. 2015 Aug;12(4):435-43
pubmed: 25415831
Am J Respir Crit Care Med. 2019 Jun 1;199(11):1312-1334
pubmed: 31149852
COPD. 2005 Jun;2(2):277-83
pubmed: 17136954
Int J Chron Obstruct Pulmon Dis. 2017 Feb 22;12:725-734
pubmed: 28260879
Proc R Soc Med. 1952 Sep;45(9):577-84
pubmed: 13003946
J Occup Environ Med. 2017 Mar;59(3):335-346
pubmed: 28267105
Eur Respir J. 1994 Jun;7(6):1048-55
pubmed: 7925872
Occup Environ Med. 1999 Jun;56(6):391-6
pubmed: 10474535
Ann Am Thorac Soc. 2021 Feb;18(2):238-246
pubmed: 33090904

Auteurs

Jate Ratanachina (J)

National Heart and Lung Institute, Imperial College London, London, UK.
Dept of Preventive and Social Medicine, King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.
Dept of Preventive and Social Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

Andre F S Amaral (AFS)

National Heart and Lung Institute, Imperial College London, London, UK a.amaral@imperial.ac.uk.

Sara De Matteis (S)

National Heart and Lung Institute, Imperial College London, London, UK.
Dept of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Herve Lawin (H)

Unit of Teaching and Research in Occupational and Environmental Health, Cotonou, Benin.

Kevin Mortimer (K)

University of Cambridge, Cambridge, UK.
Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Daniel O Obaseki (DO)

Obafemi Awolowo University, Ile-Ife, Nigeria.

Imed Harrabi (I)

Faculte de Medecine, Sousse, Tunisia.

Meriam Denguezli (M)

Faculte de Medecine, Sousse, Tunisia.

Emiel F M Wouters (EFM)

Ludwig Boltzmann Institute for Lung Health, Vienna, Austria.
Maastricht University Medical Center, Maastricht, The Netherlands.

Christer Janson (C)

Respiratory, Allergy and Sleep Research, Dept of Medical Sciences, Uppsala University, Uppsala, Sweden.

Rune Nielsen (R)

Dept of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.

Amund Gulsvik (A)

Dept of Clinical Science, Faculty of Medicine, University of Bergen, Bergen, Norway.

Hamid Hacene Cherkaski (HH)

Dept of Pneumology, Faculty of Medicine and CHU Annaba, Annaba, Algeria.

Filip Mejza (F)

Center for Evidence Based Medicine, 2nd Department of Internal Medicine, Jagiellonian University Medical College, Kraków, Poland.

Padukudru Anand Mahesh (PA)

JSS Medical College, JSSAHER, Mysuru, India.

Asma Elsony (A)

The Epidemiological Laboratory, Khartoum, Sudan.

Rana Ahmed (R)

The Epidemiological Laboratory, Khartoum, Sudan.

Wan Tan (W)

Centre for Heart Lung Innovation, University of British Columbia, Vancouver, BC, Canada.

Li Cher Loh (LC)

Royal College of Surgeons in Ireland and University College Dublin Malaysia Campus, Penang, Malaysia.

Abdul Rashid (A)

Royal College of Surgeons in Ireland and University College Dublin Malaysia Campus, Penang, Malaysia.

Michael Studnicka (M)

Dept of Pulmonary Medicine, Paracelsus Medical University, Salzburg, Austria.

Asaad A Nafees (AA)

Aga Khan University, Karachi, Pakistan.

Terence Seemungal (T)

University of the West Indies, St Augustine, Trinidad and Tobago.

Althea Aquart-Stewart (A)

University of the West Indies, Kingston, Jamaica.

Mohammed Al Ghobain (M)

College of Medicine, King Saud bin Abdulaziz University for Health Sciences, King Abdulaziz Medical City in Riyadh, Saudi Arabia.

Jinping Zheng (J)

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical College, Guangzhou, China.

Sanjay Juvekar (S)

Vadu Rural Health Program, KEM Hospital Research Centre Pune, Pune, India.

Sundeep Salvi (S)

Pulmocare Research and Education Foundation, Pune, India.

Rain Jogi (R)

Lung Clinic, Tartu University Hospital, Tartu, Estonia.

David Mannino (D)

University of Kentucky, Lexington, KY, USA.

Thorarinn Gislason (T)

Dept of Sleep, Landspitali University Hospital, Reykjavik, Iceland.
Faculty of Medicine, University of Iceland, Reykjavik, Iceland.

A Sonia Buist (AS)

Oregon Health and Science University, Portland, OR, USA.

Paul Cullinan (P)

National Heart and Lung Institute, Imperial College London, London, UK.

Peter Burney (P)

National Heart and Lung Institute, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH